Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis

Novel agents like proteasome inhibitors and immunomodulatory agents have changed the therapeutic landscape of multiple myeloma. These agents have also been studied as single agent and in combination with other agents in the treatment of AL amyloidosis.1 Systemic immunoglobulin light chain (AL) amyloidosis is a plasma cell dyscrasia leading to amyloid fibril deposition in various organs and tissues causing organ dysfunction, failure, and death....